ArticleMolecular genetics and genomics : MGG2026
HDAC7 aggravates malignant proliferation of hepatocellular carcinoma cells via the TRIM26/CBX4 axis.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a highly malignant tumor with aggressive progression and poor clinical outcomes, posing a severe threat to global health. Histone deacetylase 7 (HDAC7) has been implicated in the progression of multiple cancers, but the underlying mechanism in HCC cell proliferation remains incomplete. The present study aimed to elucidate the functional contribution of HDAC7 to HCC progression and explore the downstream regulatory network. HDAC7, TRIM26, and CBX4 expression in cells were measured. After silencing HDAC7 expression, HCC cell proliferation was detected. Histone acetylation and HDAC7 enrichment on the TRIM26 promoter were assessed. The binding between TRIM26 and CBX4 was detected. The ubiquitination level of CBX4 was measured. HDAC7 expression was upregulated in HCC cell lines. HDAC7 inhibition suppressed HCC cell proliferation. HDAC7 inhibited TRIM26 expression by mediating histone deacetylation. TRIM26 bound to CBX4 and degraded CBX4 via ubiquitination. Inhibiting TRIM26 or overexpressing CBX4 partially reversed the inhibitory effect of HDAC7 inhibition on HCC cell proliferation. HDAC7 inhibition suppressed the growth of HCC xenografts in vivo. In conclusion, HDAC7 is highly expressed in HCC cells and aggravates malignant proliferation of HCC cells via the TRIM26/CBX4 axis, highlighting HDAC7 as a potential therapeutic target for the development of anti-HCC strategies.
Indexed as
Identifiers
41779201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.